Abstract. The present study aimed to evaluate the efficacy and safety of in situ immunotherapy with dinitrophenyl (DNP) hapten in combination with laser therapy for patients with malignant melanoma (MM). Between February 2008 and March 2012, 72 patients with stage III or IV MM were enrolled. Patients received in situ DNP alone (n=32) or in combination with laser therapy (n=32), and each group received dacarbazine chemotherapy. The levels of peripheral cluster of differentiation (CD)4 + CD25 + regulatory T cells (Tregs), interleukin (IL)-10 and tumor growth factor (TGF)-β were detected by ELISA. The association between delayed-type hypersensitivity (DTH) and survival time was evaluated. Although peripheral Treg levels significantly decreased over time in the two groups (P<0.001), there was no significant difference between the treatment groups (P= 0.098). Patients receiving the combination treatment exhibited significantly higher interferon-γ production by CD8 + and CD4 + T cells (both P<0.001), as well as significantly reduced levels of IL-10, TGF-β1 and TGF-β2. In addition, patients in the combination treatment group experienced significantly longer overall survival (OS; P=0.024) and disease-free survival (DFS; P=0.007) times; a DTH response of ≥15 mm was also associated with increased OS time and DFS time (P≤0.001). Finally, no severe adverse events were observed in either treatment group. Overall, in situ immunization with DNP in combination with laser immunotherapy may activate focal T cells, producing a regional antitumor immune response that increases cell-mediated immunity and improves survival in MM patients. Thus, this may represent a novel therapeutic strategy for patients with unresectable, advanced MM.
Introduction
Derived from neural crest cells, malignant melanoma (MM) accounts for ~1.5% of all tumors and is the cutaneous malignancy with the highest mortality rate (1) . There are >10 million new cases of MM diagnosed every year (1) . In total, ~21% of MM patients present with focal skin metastasis and 50% with regional lymph node metastasis (1) . MM patients with distant metastasis (stage IV) usually have poor prognoses, with a median survival time of 5-8 months, and the ≥5-year survival rate is <2% (2) . With social and economic development, the incidence of MM is increasing each year (3) .
The poor prognosis of MM patients is reflective of the lack of an effective therapy. Systemic chemotherapy, including mono-and poly-chemotherapies, immunomodulatory therapies and vaccination therapy with dendritic cells (DCs) or genetically modified tumor cells, remains controversial (2) . Although there is evidence showing that the combined use of interleukin (IL)-2, interferon (IFN) and chemotherapeutics may achieve a response rate as high as 64% (4, 5) , the efficacy of systemic therapy remains disappointing; systemic monotherapy usually achieves a clinical response rate of <15% (6) (7) (8) (9) (10) . However, prospective, randomized clinical trials have shown no evidence that other drugs are superior to dacarbazine (DTIC) for MM patients (10) . Thus, it is imperative to identify an alternative therapeutic strategy to improve the prognosis of metastatic MM patients. Although MM is highly malignant and insensitive to chemotherapy and radiotherapy, it maintains high immunogenicity (11) . Thus, immune therapy may serve as a strategy for advanced MM. However, a hapten-modified cellular vaccine for melanoma, MVAX ® , has stalled in clinical development due to manufacturing and regulatory problems (11) .
Dinitrophenyl (DNP) is a classic hapten used to induce contact-related delayed-type hypersensitivity (DTH) due to its potent antigenicity and high absorption in healthy skin. DTH is an allergen-induced, T cell-mediated immune response that can evaluate the cellular immunity in humans (12) . However, clinical studies (11, 13) (17, 18) . Certain studies have identified increased peripheral Treg levels in patients with metastatic MM (19) (20) (21) (22) (23) ; therefore, therapies that decrease Treg levels may be beneficial for these patients.
The energy emitted by a laser may be absorbed by tissues and transformed into heat, resulting in the release and presentation of tumor antigens, and a subsequent antitumor immune response (11) . Therefore, the present study tested the hypothesis that MM patients receiving localized immunotherapy to induce DTH via DNP in combination with laser therapy would have improved disease-related outcomes as compared with patients treated with DNP alone. In addition to chemotherapy, MM patients received DTH alone or with concomitant laser therapy, and the extent of DTH, as well as the overall survival (OS) times of the patients, were determined. In addition, the levels of peripheral CD4 + CD25 + Tregs, IFN-γ-producing CD8 + T cells and CD4 + cells, IL-10, and tumor growth factor (TGF)-β were detected. The combination of immunotherapy with laser therapy may represent a novel therapeutic strategy for patients with unresectable, advanced MM. Table I ). The following inclusion criteria were employed: i) A pathological diagnosis of MM; ii) normal liver and kidney function, as well as normal results from a routine blood test; iii) a Karnofsky score of ≥60 (25) ; iv) an estimated survival time of >3 months; and v) the presence of unresectable MM (cutaneous MM with local or distant metastasis). Therapeutic efficacy was evaluated with the Response Evaluation Criteria in Solid Tumors (26) . The present study conforms to the provisions of the Declaration of Helsinki (2000 revision). Informed consent was obtained from each patient, and the study was approved by the Ethics Committee of the First Affiliated Hospital of the Chinese PLA General Hospital. The clinicaltrial.gov identifier number of the study is NCT02372708.
Materials and methods

Patients
Prior to immunotherapy, the medical history of each patient was completely reviewed, a physical examination was performed, ultrasonography was undertaken to examine the lymph nodes of the groin, armpits and neck, and cranial magnetic resonance imaging and chest/abdominal computed tomography were performed. The patients were re-examined at 3 months post-therapy, and subsequent evaluations were performed once every 3 months thereafter. Adverse events were graded according to the criteria described in the Common Terminology Criteria for Adverse Events, version 4.0 (27) .
Treatment. All the patients received DTIC-based chemotherapy. Once all the physical and laboratory examinations were performed, treatment with DTIC (200 mg/m 2 ; Nanjing Pharmaceutical Factory Co., Ltd., Nanjing, China) was initiated and performed once every 3 weeks for a total of 5 courses. When disease progression became evident, the therapy was discontinued. When stable disease or disease improvement was observed, the chemotherapy was continued. Chemotherapy was administered over a median of 5 courses (range, 2-36 courses). In the combination therapy group, 36 patients received DNP (Sinopharm Chemical Reagent Co., Ltd., Shanghai, China) with focal laser therapy. For the combination therapy group, diluted DNP-vaseline (2% DNP in 0.1 ml vaseline) was applied on the primary or metastatic lesions on the first day after chemotherapy in each course, and the lesions were concurrently irradiated with a laser for 10 min at 1 W/cm 2 and then dressed. After 2 days, the presence of contact dermatitis was confirmed. If the lymph nodes were resected, sensitization was performed at the occipital region (2x2-cm area) once weekly (28) . In the control group, 36 patients received DNP alone. Monotherapy consisted of the application of DNP-vaseline on the lesions; the remaining treatments were similar to the combination therapy group.
Prior to chemotherapy and at 2, 5, 10 and 20 days after in situ immunization, fasting venous blood was collected (10 ml) from all the patients and divided into two parts. One part was centrifuged (600 x g; 5 min; 4˚C), and the resultant serum was collected and stored at -20˚C for the detection of cytokines; the other part was anti-coagulated with heparin, and peripheral blood mononuclear cells (PBMCs) were separated by density gradient separation with lymphocyte separation medium (Sinopharm Chemical Reagent Co., Ltd.). The PBMCs were counted, and cell density was adjusted to 1-2x10 6 cells/ml and analyzed by flow cytometry.
Flow cytometry. Using PBMCs, CD8
+ and CD4 + T cells were screened separately with 10 µl/10 7 cells of anti-CD8 monoclonal antibody magnetic Dynabeads (Life Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and anti-CD4 monoclonal antibody magnetic MicroBeads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Once the beads were removed, the CD8 + and CD4 + T cells were blocked using blocking reagents (eBioscience, Inc., San Diego, CA, USA) for 30 min at 4˚C, and independently labeled with 10 µl of each antibody against CD4-fluorescein isothiocyanate (FITC) (mouse monoclonal; catalogue no. 11-0047-42), CD8-FITC (mouse monoclonal; catalogue no. 11-0088-42) and IFN-γ-phycoerythrin (PE) (mouse monoclonal; catalogue no. 12-7319-42) (eBioscience, Inc.) in 1 ml of staining buffer (1:100 dilution; eBioscience, Inc.). Labeled cells were detected and analyzed by a FACSCanto analyzer (BD Biosciences, Franklin Lakes, NJ, USA).
For the analysis of Tregs, the PBMCs (100 µl) were also mixed with 10 µl of FITC-conjugated mouse anti-human CD4 (eBioscience, Inc.) or PE-conjugated CD25 (eBioscience, Inc.) antibodies, followed by incubation in the dark for 30 min at 4˚C Upon washing in PBS twice, 500 µl of PBS was added, and CD4 + CD25 + Tregs were detected by flow cytometry.
ELISA. ELISA was performed to detect the serum levels of IL-10 (IL-10 ELISA kit; R&D Systems, Inc., Minneapolis, MN, USA), TGF-β1 and TGF-β2 (TGF-β1/β2 ELISA kit; R&D Systems, Inc.) according to the manufacturer's protocol.
Antibody titration assay. Blood samples (5 ml) were collected prior to immunization to establish background antibody levels, and thereafter they were collected every 2 weeks. After the blood samples were allowed to clot at room temperature for ≤1 h, they were then centrifuged at 12,000 x g for 5 min. Serum fractions were collected and diluted 10-fold in PBS. Anti-DNP immunoglobulin G titers were determined by ELISA, as previously described (18) . Absorbance was measured at 492 nm using a 3550 microplate reader (Bio-Rad Laboratories, Inc, Hercules, CA, USA). Best-fit sigmoidal curves were obtained from plotting the absorbance vs. the logarithmic dilution factors using GraphPad Prism 4 (GraphPad Software, Inc., La Jolla, CA, USA). Titer levels were obtained as half maximal effective concentration values from the midpoint of each sigmoidal curve.
DTH scoring. DTH was assessed as previously described (29) . After DNP application, swelling and even blistering was observed 12-24 h later, but it resolved within 2-5 days. When swelling was present again 1-2 weeks later, an allergy was suggested, and the swelling was scored as ++++ (diameter, ≥20 mm) or +++ (diameter, ≥15-<20 mm). In the event that there was no response within 1-2 weeks, 50 µg DNP was reapplied to the lesion, and the response was observed 24 h later. Swelling was scored as ++ (diameter, ≥10-<15 mm), + (diameter, <10 mm) or negative (in the absence of swelling).
Statistical analysis. Baseline demographic and clinical characteristics are presented as a number and percentage. χ 2 tests were used to examine the associations between baseline characteristics and treatment groups. As blood samples were collected at baseline (day 0) and on days 2, 5, 10 and 20, a mixed-effects model was used to evaluate group and time effects on changes in the levels of T cells and inhibitory cytokines by taking into account the repeated measures design. Post-hoc multiple comparisons were made between groups and time points with Bonferroni correction. OS time was defined as the time elapsed from the date of surgery to the date of mortality. Disease-free survival (DFS) time was defined as the time elapsed from the date of surgery to the date of the first swelling/blistering. To evaluate differences in OS time and DFS time between treatment and DTH response groups, Kaplan-Meier survival analyses were performed. Log-rank tests were conducted to examine differences in OS time and DFS time between the groups. All statistical analyses were performed using SPSS statistical software version 22 for Windows (IBM SPSS, Armonk, NY, USA). A two-tailed P-value of <0.05 was considered to indicate a statistically significant difference.
Results
Baseline demographics and clinical characteristics.
There were 36 patients in the treatment group (23 male cases and 13 female cases) and 36 cases in the control group (16 male cases and 20 female cases). The mean age of the patients was 60.0 years (range, 29-85 years). As shown in Table I , the majority of the patients were <70 years old (72.2 and 63.9% for the DNP monotherapy and combination therapy groups, respectively), and ~1/2 of the patients were diagnosed with stage IV melanoma. All demographic and clinical characteristics were comparable between the monotherapy control and combination treatment groups (all P>0.05; Table I ).
Effects of immunotherapy combined with laser therapy on peripheral Treg levels. As shown in Fig. 1 , the levels of peripheral Tregs significantly decreased over time in each group (P<0.001). However, there was no significant difference between the combination therapy groups after considering repeated measurements across time (P=0.098). Kaplan-Meier analysis of survival rates revealed that the patients in the combination treatment group experienced significantly longer OS times than those in the monotherapy group (P= 0.024; Fig. 4A ). Furthermore, the 1-year DFS rate was 44.0 and 69.1% in the monotherapy and combination therapy treatment groups, respectively. Log-rank analysis revealed that the patients in the combination therapy group experienced a longer DFS time than those in the monotherapy group (19.0 vs. 12.0 months, respectively; P=0.007; Fig. 4B ).
Combination therapy increases IFN-γ secretion by T cells and significantly reduces inhibitory
Patients with a DTH response of ≥15 mm experienced a longer OS time than patients with a DTH response of <15 mm (30.0 vs. 16.0 months, respectively; P<0.001; Fig. 4C ). In addition, log-rank analysis revealed that patients with a DTH response of <15 mm experienced a longer DFS time than those with a DTH response of <15 mm (20.0 vs. 10.0 months, respectively; P=0.001; Fig. 4D ).
Evaluation of safety.
No severe adverse events were observed in any of the 72 patients enrolled in the present study. The most common side effects included a low-grade fever and fatigue (Table II) . Thus, in situ immunotherapy with DNP in combination with laser therapy demonstrated favorable efficacy and an acceptable safety profile.
Discussion
For the majority of patients with stage IV MM, the survival time is ≤1 year after diagnosis (29) due in large part to the lack of an effective therapy. As MM maintains high immunogenicity (11), the present study aimed to compare the clinical outcomes in MM patients receiving localized immunotherapy to induce DTH via DNP in combination with laser therapy against those observed in patients treated with DNP alone. DNP monotherapy and combination therapy decreased Treg levels over time to a similar extent. However, patients receiving the combination treatment exhibited significantly higher IFN-γ production by CD8 + and CD4 + T cells, and significantly reduced levels of IL-10, TGF-β1 and TGF-β2 than the control group. Furthermore, the patients in the combination treatment group experienced significantly longer OS and DFS times than the control group. Given that no severe adverse events were observed in either treatment group, which is consistent with our previous study (30) , DNP treatment combined with laser immunotherapy may represent a novel therapeutic strategy for advanced MM. These results are consistent with other previous studies, which reported that laser immunotherapy in combination with immune adjuvant therapy could achieve strong immune responses in MM and breast cancer patients (31-33).
Terheyden et al (34) used dinitrochlorobenzene to induce contact dermatitis, which in combination with DTIC therapy, was used to treat metastatic MM. The objective response rate was 62% in patients with stage III MM (n=39) and 9% in those with stage IV MM (n=33), and >50% of patients remained progression-free for 1 year regardless of the stage of MM (35) . In the present study, DNP hapten was used to induce DTH through DNP-mediated activation of T cells. MHC presentation of the hapten by antigen-presenting cells can also induce the production of tumor antigens, which may cause cross-antigen presentation (12) . Subsequent hapten-induced presentation of tumor antigens can be recognized by the immune system (13) . Cutaneous DTH could be used as an indicator to evaluate immune therapy (35) , as well as being a predictor of survival (36) . In 27 patients with stage IV MM receiving a DC vaccine to induce DTH, the median survival time was 22.9 months (n=19) in DTH-positive patients and 4.8 months in DTH-negative patients (37) . Similarly, in the present study, the extent of the DTH reaction was associated with OS and DFS. By contrast, in a study of 284 melanoma patients treated with an autologous tumor cell vaccine in combination with DNP, a positive DTH response (≥5 mm) was not associated with the number of living melanoma cells, but with the number of dead tumor cells (36) . Thus, further studies will determine if combination therapy is associated with tumor cell death.
Along with the extent of DTH, combination therapy was associated with increased OS and DSF times in the present study. As local radiotherapy is associated with the regression of metastatic cancer at a distance from the irradiated site, a phenomenon called the abscopal effect may be observed, which may be mediated by a systemic immune response (38) .
Further studies will assess whether the increased OS and DFS times in patients receiving combination therapy were associated with reduced metastasis.
The extent of DTH induced by chemoimmunotherapy is also consistent with an increase in the proportion of CD8 + -IFN-γ + cells (39, 40) . In the present study, increased proportions of IFN-γ-producing CD8 + and CD4 + T cells were observed over time with each treatment; however, the proportions were significantly greater in the patients receiving combination therapy. These results suggested that the extent to which DTH was induced was greater with combination therapy than with monotherapy. Adverse events  0  1  2  3  4   Fever  56  10  4  2  0  Fatigue  49  16  5  2  0  Neutropenia  65  4 Tregs have an essential role in sustaining self-tolerance and immune homeostasis by suppressing a number of physiological and pathological immune responses, including those in the tumor microenvironment (19) . In the present study, the levels of peripheral CD4 + CD25 + Tregs decreased in the two treatment groups; however, no differences between the groups were noted over time. The decrease in Treg levels coincided with reduced serum levels of inhibitory cytokines, including IL-10, TGF-β1 and TGF-β2. Furthermore, the suppression of these cytokines was significantly greater in patients receiving combination therapy at days 5, 10 and 20. These results are consistent with those reported for patients treated with a vaccine consisting of melanoma cells with DNP, in which OS time was reduced in patients with high IL-10 levels in the tumor microenvironment (41) .
The present study is limited by its relatively small sample size. Therefore, additional studies with larger numbers of patients and studies taking place at different institutions are necessary to confirm the results of the present study. In addition, the patients in the present study were sensitized to DNP via its topical application; therefore, further studies assessing the possible additive effects of using laser therapy with a previously described DNP-modified melanoma cell vaccine are necessary (33, 40) . Finally, the mechanism by which combination therapy enhances OS and DFS was not examined. It is possible that the localized treatment impacted the incidence of metastasis or reduced metastatic lesions through the abscopal effect, which will be analyzed in further studies (38, 42) .
Taken together, the present results indicate that the cutaneous application of DNP may induce a highly specific systemic immune response that can be enhanced with laser therapy. This immune response may reduce the incidence of distant metastases, which may improve the survival time of MM patients. Thus, given that no severe adverse events were observed in either treatment group, DNP treatment combined with laser immunotherapy may represent a novel therapeutic strategy for advanced MM.
